A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

Cell 2015 Jul;162(1):146-59

Department I of Internal Medicine, University Hospital Cologne, Weyertal 115B, 50931 Cologne, Germany; CECAD, University of Cologne, Weyertal 115B, 50931 Cologne, Germany. Electronic address:

KRAS is one of the most frequently mutated oncogenes in human cancer. Despite substantial efforts, no clinically applicable strategy has yet been developed to effectively treat KRAS-mutant tumors. Here, we perform a cell-line-based screen and identify strong synergistic interactions between cell-cycle checkpoint-abrogating Chk1- and MK2 inhibitors, specifically in KRAS- and BRAF-driven cells. Mechanistically, we show that KRAS-mutant cancer displays intrinsic genotoxic stress, leading to tonic Chk1- and MK2 activity. We demonstrate that simultaneous Chk1- and MK2 inhibition leads to mitotic catastrophe in KRAS-mutant cells. This actionable synergistic interaction is validated using xenograft models, as well as distinct Kras- or Braf-driven autochthonous murine cancer models. Lastly, we show that combined checkpoint inhibition induces apoptotic cell death in KRAS- or BRAF-mutant tumor cells directly isolated from patients. These results strongly recommend simultaneous Chk1- and MK2 inhibition as a therapeutic strategy for the treatment of KRAS- or BRAF-driven cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.05.053DOI Listing
July 2015
63 Reads

Publication Analysis

Top Keywords

chk1- mk2
20
kras- braf-driven
12
mk2 inhibitors
8
kras-mutant cancer
8
simultaneous chk1-
8
mk2 inhibition
8
synergistic interaction
8
mk2
5
chk1-
5
genotoxic stress
4
apoptotic cell
4
displays intrinsic
4
stress leading
4
intrinsic genotoxic
4
induces apoptotic
4
mk2 activity
4
cancer displays
4
leading tonic
4
tonic chk1-
4
death kras-
4

Similar Publications